BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial-Reference-Cited by-同舟云学术

BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial

Published:2016-05-05 Issue:4 Volume:139 Page:882-889
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Schouten Philip C.¹,Gluz Oleg²³,Harbeck Nadia²⁴,Mohrmann Svjetlana⁵,Diallo-Danebrock Raihana⁵,Pelz Enrico³,Kruizinga Janneke⁶,Velds Arno⁶,Nieuwland Marja⁶,Kerkhoven Ron M.⁶,Liedtke Cornelia²⁷,Frick Markus²,Kates Ronald²,Linn Sabine C.¹⁸,Nitz Ulrike²³,Marme Frederik⁹¹⁰

Affiliation:

1. Department of Molecular Pathology; Netherlands Cancer Institute; Amsterdam The Netherlands

2. West German Study Group; Germany

3. Breast Centre Niederrhein; Moenchengladbach Germany

4. Brustzentrum; Ludwig-Maximillian University Munich; Germany

5. Universitäts-Frauenklinik Duesseldorf; Germany

6. Genomics Core Facility; NKI-AVL; Amsterdam The Netherlands

7. Universitäts-Frauenklinik Lübeck; Germany

8. Division of Medical Oncology; Netherlands Cancer Institute, Amsterdam; The Netherlands Department of Pathology; University Medical Center Utrecht; Utrecht The Netherlands

9. Universitäts-Frauenklinik, University of Heidelberg; Germany

10. National Center for Tumour Diseases; University of Heidelberg; Germany

Funder

A Sister's Hope

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference33 articles.

1. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial;Gluz;Ann Oncol,2008

2. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage;Chen;Breast Cancer Res Treat,2014

3. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study;Walters;Br J Cancer,2013